SNCA and Parkinson disease: Although large, randomized, controlled trials are still needed to clarify the effects of β2AR agonists on the risk of PD [127], it is worth highlighting that H3K27 acetylation of SNCA can be regulated in a level-dependent manner by both β2AR agonists (down) and antagonists (up) [94].